Prof Christopher R Chapple MDConsultant Urological Surgeon, Sheffield Teaching Hospitals NHS Foundation Trust, Honorary Professor, University of Sheffield, Visiting Professor, Sheffield Hallam University, Secretary General, European Association of Urology, CPMS Implementation Leader, ERN eUROGEN, Sheffield, United Kingdom
Professor Christopher Chapple is a Consultant Urological Surgeon at Sheffield Teaching Hospitals and Visiting Professor at Sheffield Hallam University. He has a particular interest in functional reconstruction of the lower urinary tract and the underlying pharmacological control mechanisms and provides a tertiary service in lower urinary tract reconstructive surgery. He trained at the Middlesex Hospital where he subsequently completed his doctorate thesis, and continued there and at the Institute of Urology in London for his sub-specialist training.
He is Chairman of the International Relations Committee at the European Association of Urology, having previously been the Adjunct Secretary General responsible for Education and Past Director of the European School of Urology. He is editor-in-chief of the journal Neurourology and Urodynamics and is on the editorial board of several journals such as the British Journal of Urology, European Urology, Surgery and Current Opinion in Urology. He is an active member of many international urological associations and societies including the British Association of Urological Surgeons, the European Association of Urology, the International Continence Society, the Association of Academic European Urologists and the American Association of Genitourinary Surgeons. He has chaired a number of guidelines initiatives including the NICE Guidelines Development Group on male lower urinary tract symptoms. He was awarded the St Peter’s medal by the British Association of Urological Surgeons in 2011. Professor Chapple has co-authored over 350 articles in peer-reviewed Journals and has written several books and a number of book chapters.
Recent Contributions to PracticeUpdate:
- Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
- The Efficacy and Safety of Vibegron in Treating Overactive Bladder
- Prediction Model of Detrusor Underactivity in Men With LUTS
- 1-Year Results of Selective Bladder Denervation in Women With Refractory OAB
- Anticholinergic Drug Exposure and the Risk of Dementia
- OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients With Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial